Role of 5-HT(1A) receptors in the ability of mixed 5-HT(1A) receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats

European Journal of Pharmacology

Volumn 313, Issue 1-2, 1996, Pages 25-34

  Kleven, Mark ^a   Prinssen, Eric P M ^a   Koek, Wouter ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

5 HT(1A) receptor agonist; 8 OH DPAT (( ) 8 hydroxy 2 (di n propylamino)tetralin); BMS 181100; BMY 14802; Buspirone; Clozapine; Flesinoxan; Gnawing; Haloperidol; Methylphenidate; S 14506

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; BUSPIRONE; CLOZAPINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLESINOXAN; HALOPERIDOL; METHYLPHENIDATE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; SEROTONIN 1 AGONIST; SEROTONIN 1A RECEPTOR; ANXIOLYTIC AGENT; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; SEIZURE; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHYLPHENIDATE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; SEROTONIN AGONISTS;

EID: 0030578928     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00498-0     Document Type: Article

References (52)

1. Ahlenius, S., 1989, Antipsychotic-like properties of the 5-HT1A agonist 8-OH-DPAT in the rat, Pharmacol. Toxicol. 64, 3.
2. Ahlenius, S., V. Hillegaart and A. Wijkström, 1989, Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat, Naunyn-Schmiedeberg's Arch. Pharmacol. 339, 551.
3. Ahlenius, S., V. Hillegaart and A. Wijkström, 1991, Behavioral and biochemical effects of the 5-HT1A receptor agonists flesinoxan and 8-OH-DPAT in the rat, Eur. J. Pharmacol. 200, 259.
4. Casey, D.E., 1993, Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates, Psychopharmacology 112, S55.
5. Chen, N.-H. and M.E.A. Reith, 1995, Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (±)-8-hydroxy-2-(di-n-propylamino)tetralin, J. Neurochem. 64, 1585.
6. Colpaert, F.C., W. Koek, J. Lehmann, J.M. Rivet, F. Lejeune, H. Canton, K. Bervoets, M.J. Millan, M. Laubie and G. Lavielle, 1992, S 14506: a novel, potent, high-efficacy 5-HT1A agonist and potential anxiolytic agent, Drug Dev. Res. 26, 21.
7. Debonnel, G. and C. de Montigny, 1996, Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders, Life Sci. 58, 721.
8. Forster, E.A., I.A. Cliffe, D.J. Bill, G.M. Dover, D. Jones, Y. Reilly and A. Fletcher, 1995, A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635, Eur. J. Pharmacol. 281, 81.
9. Fray, P.J., B.J. Sahakian, T.W. Robbins, G.F. Koob and S.D. Iversen, 1980, An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine, Psychopharmacology 69, 253.
10. Gerlach, J. and L. Peacock, 1995, New antipsychotics: the present status, Intl. Clin. Psychopharmacol. 10, 39.
11. Gewirtz, G.R., J.M. Gorman, J. Volavka, J. Macaluso, G. Gribkoff, D.P. Taylor and R. Borizon, 1994, BMY 14802, a sigma receptor ligand for the treatment of schizophrenia, Neuropsychopharmacology 10, 37.
12. Goff, D.C., K.K. Midha, A.W. Brotman, S. Mc Cormick, M. Waites and E.T. Amico, 1991, An open trial of buspirone added to neuroleptics in schizophrenic patients, J. Clin. Psychopharmacol. 11, 193.
13. Hubert, J.J., 1984, Bioassay (Kendall/Hunt, Dubuque).
14. Ichikawa, J., T. Juroki, M.T. Kitchen and H.Y. Meltzer, 1995, R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens, Eur. J. Pharmacol. 287, 179.
15. Irwin, S., 1968, Comprehensive observational assessment: Ia: a systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse, Psychopharmacologia 13, 222.
16. Jackson, D.M., N. Moherll, A. Bengtsson and Å. Malmberg, 1993, What are atypical neuroleptics and how do they work?, in: New Generation of Antipsychotic Drugs: Novel Mechanisms of Action, eds. N. Drunello, J. Mendlewicz and G. Racagni (Karger) p. 27.
17. Johnson, E.A., C.E. Tsai, S.Y. H and A.J. Azzaro, 1993, Serotonin 5-HT1A receptors mediate inhibition of tyrosine hydroxylation in rat striatum, J. Pharmacol. Exp. Ther. 266, 133.
18. Kapur, S., G. Remington, R.B. Zipursky, A.A. Wilson and S. Houle, 1995, The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a pet study, Life Sci. 53, PL103.
19. Koek, W. and F.C. Colpaert, 1993, Inhibition of methylphenidate-induced behaviors in rats: differences among neuroleptics, J. Pharmacol. Exp. Ther. 267, 181.
20. Lewander, T., 1977, Effects of amphetamine in animals, in: Drug Addiction II (Springer) p. 33.
21. Liebman, J.M., S.C. Gerhardt and R. Gerber, 1989, Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction, Psychopharmacology 97, 456.
22. Lowe, J.A.I., T.F. Seeger, A.A. Nagel, H.R. Howard, P.A. Seymour, J.H. Heym, F.E. Ewing, M.E. Newman, A.W. Schmidt, J.S. Furman, L.A. Vincent, P.R. Maloney, G.L. Robinson, L.S. Reynolds and F.J. Vinick, 1991, 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents, J. Med. Chem. 34, 1860.
23. Maskall, D.D., A.P. Zis, R.W. Lam, C.M. Clark and A.J. Juan, 1995, Prolactin response to buspirone challenge in the presence of dopaminergic blockade, Biol. Psychiatry 38, 235.
24. McMillen, B.A., S.M. Scott and E.A. Davanzo, 1988, Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs, J. Pharm. Pharmacol. 40, 885.
25. Meltzer, H.Y., S. Matsubara and J.-C. Lee, 1989, Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values, J. Pharmacol. Exp. Ther. 251, 238.
26. Moore, K.E., 1978, Amphetamines: biochemical and behavioral actions in animals, in: Handbook of Psychopharmacology: Stimulants (Plenum) p. 41.
27. Moore, N.A., N.C. Type, M.S. Axton and F.C. Risius, 1992, Behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent, J. Pharmacol. Exp. Ther. 262, 545.
28. Moore, N.A., D.E. Tupper and T.M. Hotten, 1994, Olanzapine, Drugs Future 19, 114.
29. Neal-Beliveau, B., J.N. Joyce and I. Lucki, 1993, Serotonergic involvement in haloperidol-induced catalepsy, J. Pharmacol. Exp. Ther. 265, 207.
30. New, J.S., 1990, The discovery and development of buspirone: a new approach to the treatment of anxiety, Med. Res. Rev. 10, 283.
31. Newman-Tancredi, A., C. Chaput, L. Verriele and M.J. Millan, 1996, Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors, Neuropharmacology 35, 119.
32. Pantelis, C. and T.R.E. Barnes, 1993, Acute exacerbation of psychosis with buspirone, J. Psychopharmacol. 7, 295.
33. Peroutka, S.J., 1985, Selective interaction of novel anxiolytics with 5-hydroxytryptamine 1A receptors, Biol. Psychiatry 20, 971.
34. Perregaard, J., K. Andersen, J. Hyttel and C. Sanchez, 1992, Selective, centrally acting serotonin 5-HT2 antagonists. 1, 2-and 6-substituted-1-phenyl-3-(4-piperidinyl)-1 H-indoles, J. Med. Chem. 35, 4813.
35. Perrone, R., F. Berardi, N.A. Colabufo, V. Tortorella, F. Fiourentini, V. Olgiati, E. Vanotti and S. Govoni, 1994, Mixed 5-HT1A/D2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalene-4-yl)-n-propyl]piperazines, I. Synthesis and structure-activity relationships, J. Med. Chem. 37, 99.
36. Protais, P., A. Chagraoui and J, Arbaoui, 1994, Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents, Eur. J. Pharmacol. 271, 167.
37. Rabin, R.A. and J.C. Winter, 1993, Studies of the biochemical basis for the discriminative properties of 8-hydroxy-2(di-n-propylamino)tetralin, Eur. J. Pharmacol. 235, 237.
38. Reitz, A.B., E.W. Baxter, D.J. Bennett, E.E. Codd, A.D. Jordan, E.A. Malloy, B.E. Maryanoff, M.E. McDonnell, M.E. Ortegon, M.J. Renzi, M.K. Scott, R.P. Shank, R.G. Sherrill, J.L. Vaught and D.J. Wustrow, 1995, N-aryl-N'-benzylpiperazines as potential antipsychotic agents, J. Med. Chem. 38, 4211.
39. Sanger, D.J. and H. Schoemaker, 1992, Discriminative stimulus properties of 8-OH-DPAT: relationship to affinity for 5HT1A receptors, Psychopharmacology 108, 85.
40. Sathananthan, G.L., I. Sanghvi, N. Phillips and S. Gershon, 1975, MJ9022: correlation between neuroleptic potential and stereotypy, Curr. Ther. Res. 18, 701.
41. Seeger, T.F., P.A. Seymour, A.W. Schmidt, S.H. Zorn, D.W. Schulz, L.A. Lebel, S. McLean, V. Guanowsky, H.R. Howard, I. Lowe and J. Heym, 1995, Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity, J. Pharmacol. Exp. Ther. 275, 101.
42. Skarsfeldt, T., 1995, Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat, Eur. J. Pharmacol. 281, 289.
43. Skarsfeldt, T. and J. Perregaard, 1990, Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat, Eur. J. Pharmacol. 182, 613.
44. Tallarida, R.J. and R.G. Murray, 1987, Manual of Pharmacological Calculations with Computer Programs (Springer, New York).
45. Terleckyj, I. and P.K. Sonsalla, 1994, The sigma receptor ligand (±)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors, J. Pharmacol. Exp. Ther. 269, 44.
46. Tollefson, G.D., S.P. Lancaster and J. Montague-Clouse, 1991, The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency, Psychopharmacol. Bull. 27, 163.
47. Waddington, J.L., 1986, Psychopharmacological studies in rodents: stereotaxic intracerebral injections and behavioural assessment, in: Working Methods in Neuropsychopharmacology, eds. M.H. Joseph and J.L. Waddington (Manchester University Press, Manchester) p. 1.
48. Wadenberg, M.L. and S. Ahlenius, 1988, Suppression of conditioned avoidance by 8-O-DPAT in the rat, J. Neural Transm. 74, 195.
49. Wadenberg, M.L., L. Cortizo and S. Ahlenius, 1994, Evidence for specific interactions between 5-HT1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat, Pharmacol. Biochem. Behav. 47, 509.
50. Wu, Y.H., J.W. Raybum, L.E. Allen, H.C. Ferguson and J.W. Kissel, 1972, Psychosedative agents. 2,8-(4-substituted 1-piperazinylalkyl)-8-azaspiro[4,5]decane-7,9-diones, J. Med. Chem. 15, 477.
51. 1A receptor agonist flesinoxan, Eur. J. Pharmacol. 256, 141.
52. Yocca, F.D., 1990, Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors, J. Clin. Psychopharmacol. 10 (Suppl. 3), 6.